This compound was previously known as Cethrin. Dr Lisa McKerracher is Founder of BioAxone and inventor of Cethrin. It is being developed by Vertex Pharmaceuticals.
UC Davis Health System – Sacramento, California – Neurosurgeons at UC Davis Health System have enrolled the first patient in a study that will determine if a new investigational treatment can safely and effectively improve motor function following acute traumatic cervical spinal cord injury. The treatment, a compound known as VX-210 being developed by Vertex Pharmaceuticals, could potentially block a molecule that plays a major role in preventing nerve regeneration.
The first patient was treated by Ripul Panchal, assistant professor of neurological surgery. The study will eventually include about 150 patients at 35 sites in North America.
Participants must be between 14 and 75 years of age and scheduled to undergo a spinal decompression/stabilization surgery within 72 hours following the initial injury. They will be randomized into three groups: two will receive the compound at two different doses and another will receive a placebo to the site of their injuries during surgery. At least four follow-up evaluations within 12 months after the surgical procedure are required for all participants.
For additional information and enrollment criteria for the VX-210 study at UC Davis, contact Nancy Rudisill at 916-734-3660 or firstname.lastname@example.org or visit clinicaltrials.gov.